ArticleAmerican journal of hematology2026
Relapse Thresholds (12/24 Mo) Define Survival Disparity in Pediatric B-ALL.
Article in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
This study systematically analyzed relapse patterns in pediatric B-cell acute lymphoblastic leukemia (B-ALL) across 2930 patients from the TARGET and MP2PRT cohorts, with an additional 2972 patients from four independent external validation cohorts, to define clinically relevant prognostic thresholds. Monthly landmark-based Cox analyses identified 13 months as the time point with the peak hazard ratio (HR = 31.97) and 27 months as the time point with the maximum -log10P value (158.08); given the small differences from 12 and 24 months and their greater clinical practicality, POD12 (progression of disease within 12 months) and POD24 (progression of disease within 24 months) were selected as clinically practical landmarks for subsequent analyses. In the TARGET and MP2PRT cohorts, POD12 occurred in 2.56% of patients and POD24 in 8.67%. Patients with POD12 had a 5-year overall survival (OS) of 11.13% versus 90.89% in non-POD12 patients, whereas patients with POD24 had a 5-year OS of 36.19% versus 93.62% in non-POD24 patients. In all four external validation cohorts, POD12 and POD24 were likewise associated with significantly inferior OS compared with their respective non-POD groups. In univariate analyses, E2A-PBX1 and MLL rearrangements were associated with increased risk of POD12 and POD24. These findings support POD12 and POD24 as clinically practical, data-driven landmarks for identifying patients with adverse survival outcomes. They may also inform the exploratory evaluation of 1-year and 2-year progression-free survival as hypothesis-generating candidate early trial endpoints, pending prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.